WebFeb 15, 2024 · Trial Design: Trop-2 Investigation in Cancer with Sacituzumab (TROPiCS-02; NCT03901339) is a randomized, open-label, phase 3 study in pts with HR+/HER2- MBC and ≥1 measurable target lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 after failure of ≥2, but ≤4 prior chemotherapy regimens. WebIn TROPiCS-02 (NCT03901339), SG showed significant progression-free survival (PFS) benefit vs TPC in ET resistant HR+/HER2- mBC (HR, 0.66; P. 0.001; median 5.5 vs 4.0 mo; …
Trodelvy® Significantly Improves Overall Survival in Pre …
WebSep 9, 2024 · The TROPiCS-02 study had previously met its primary endpoint of statistically significant PFS benefit with sacituzumab govitecan. The median PFS with TROPiCS-02 was 5.5 months and the 12-month PFS rate was 21% versus treatment of physician’s choice, in which the median PFS was 4.0 months, and the 12-month PFS rate was 7%. WebMar 9, 2024 · Gilead Sciences announced results from the phase 3 TROPiCS-02 study for sacituzumab govitecan-hziy (Trodelvy) in individuals with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who received prior endocrine therapy, DSK/6 inhibitors, and 2 to 4 lines of chemotherapy.. … horton rkatsiteli
Gilead Sciences, Inc. - Trodelvy® Significantly Improved Overall ...
WebSep 9, 2024 · Abstract presented: Rugo HS, et al. Overall survival (OS) results from the phase 3 TROPICS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (MBC) ESMO Congress 2024, LBA76. Proffered Paper Session – Breast cancer, metastatic, 09.09.2024, h. 16:00 – … WebSep 7, 2024 · The TROPiCS-02 study is a global, multicenter, open-label, Phase 3 study, randomized 1:1 to evaluate Trodelvy versus physicians’ choice of chemotherapy (eribulin, capecitabine, gemcitabine, or vinorelbine) in 543 patients with HR+/HER2- metastatic breast cancer who were previously treated with endocrine therapy, CDK4/6 inhibitors and two to … WebNov 7, 2024 · In TROPiCS-02 the drug Sacituzumab Govitecan-hziy (also known as Trodelvy®) was compared to Treatment of Physician's Choice in patients with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) metastatic breast cancer. horton päänsärky